Huntington Disease - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Huntington Disease - Pipeline Review, H1 2016

Huntington Disease - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Huntington Disease - Pipeline Review, H1 2016
Published May 31, 2016
303 pages — Published May 31, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Huntington Disease - Pipeline Review, H1 2016, provides an overview of the Huntington Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Huntington Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Huntington Disease and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Huntington Disease
- The report reviews pipeline therapeutics for Huntington Disease by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Huntington Disease therapeutics and enlists all their major and minor projects
- The report assesses Huntington Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Huntington Disease

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Huntington Disease
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Huntington Disease pipeline depth and focus of In

  
Source:
Document ID
GMDHC8162IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents215
  List of Tables142
  List of Figures161
Introduction171
  Global Markets Direct Report Coverage171
Huntington Disease Overview181
Therapeutics Development192
  Pipeline Products for Huntington Disease Overview191
  Pipeline Products for Huntington Disease Comparative Analysis201
Huntington Disease Therapeutics under Development by Companies214
Huntington Disease Therapeutics under Investigation by Universities/Institutes252
Huntington Disease Pipeline Products Glance273
  Late Stage Products271
  Clinical Stage Products281
  Early Stage Products291
Huntington Disease Products under Development by Companies304
Huntington Disease Products under Investigation by Universities/Institutes341
Huntington Disease Companies Involved in Therapeutics Development3552
  Addex Therapeutics Ltd351
  AFFiRiS AG361
  Angita B.V.371
  Astellas Pharma Inc.381
  Azevan Pharmaceuticals, Inc.391
  BioCrea GmbH401
  BioMarin Pharmaceutical Inc.411
  BrainStorm Cell Therapeutics Inc.421
  Diffusion Pharmaceuticals Inc.431
  EncephRx, Inc.441
  Evotec AG451
  Galenea Corp.461
  Genervon Biopharmaceuticals, LLC471
  Immungenetics AG481
  Ionis Pharmaceuticals, Inc.491
  Ipsen S.A.501
  Kadmon Corporation, LLC511
  KineMed, Inc.521
  Living Cell Technologies Limited531
  Medesis Pharma S.A.541
  Mitochon Pharmaceuticals, Inc.551
  Neuralstem, Inc.561
  Neurimmune Holding AG571
  NeuroNascent, Inc.581
  New World Laboratories, Inc.591
  nLife Therapeutics, S.L.601
  NsGene A/S611
  Omeros Corporation621
  Oryzon Genomics S.A.631
  Otsuka Holdings Co., Ltd.641
  Pfizer Inc.651
  PharmatrophiX, Inc.661
  ProQR Therapeutics N.V.671
  QR Pharma, Inc.681
  Raptor Pharmaceutical Corp.691
  reMYND NV701
  Rhenovia Pharma Limited711
  Sangamo BioSciences, Inc.721
  SOM Innovation Biotech SL731
  Spark Therapeutics, Inc.741
  Teva Pharmaceutical Industries Ltd.751
  TyrNovo Ltd.761
  Ultragenyx Pharmaceutical Inc.771
  UniQure N.V.781
  Vaccinex, Inc.791
  Vertex Pharmaceuticals Incorporated801
  VistaGen Therapeutics , Inc.811
  VivaCell Biotechnology Espana S.L.821
  Voyager Therapeutics, Inc.831
  Vybion, Inc.841
  WAVE Life Sciences Ltd.851
  Wellstat Therapeutics Corporation861
Huntington Disease Therapeutics Assessment8711
  Assessment by Monotherapy Products871
  Assessment by Target883
  Assessment by Mechanism of Action913
  Assessment by Route of Administration942
  Assessment by Molecule Type962
Drug Profiles98132
  AK-7 - Drug Profile981
    Product Description981
    Mechanism of Action981
    R&D Progress982
  AMT-130 - Drug Profile1001
    Product Description1001
    Mechanism of Action1001
    R&D Progress1001
  Antisense Oligonucleotide 1 to Inhibit Huntingtin Protein for Huntington Disease - Drug Profile1011
    Product Description1011
    Mechanism of Action1011
    R&D Progress1011
  Antisense Oligonucleotide 2 to Inhibit Huntingtin Protein for Huntington Disease - Drug Profile1021
    Product Description1021
    Mechanism of Action1021
    R&D Progress1021
  Antisense Oligonucleotide to Inhibit HTT for Huntington Disease - Drug Profile1031
    Product Description1031
    Mechanism of Action1031
    R&D Progress1031
  Antisense Oligonucleotides to Inhibit Huntingtin Protein for Huntington Disease - Drug Profile1041
    Product Description1041
    Mechanism of Action1041
    R&D Progress1041
  ASP-2905 - Drug Profile1051
    Product Description1051
    Mechanism of Action1051
    R&D Progress1051
  AV-101 - Drug Profile1061
    Product Description1061
    Mechanism of Action1061
    R&D Progress1062
  AVP-786 - Drug Profile1081
    Product Description1081
    Mechanism of Action1081
    R&D Progress1082
  BN-82451 - Drug Profile1101
    Product Description1101
    Mechanism of Action1101
    R&D Progress1101
  Carbenoxolone sodium - Drug Profile1111
    Product Description1111
    Mechanism of Action1111
    R&D Progress1111
  Cell Therapy for Huntington Disease, Amyotropic Lateral Sclerosis and Parkinson's Disease - Drug Profile1121
    Product Description1121
    Mechanism of Action1121
    R&D Progress1121
  CNB-001 - Drug Profile1131
    Product Description1131
    Mechanism of Action1131
    R&D Progress1132
  CP-2 - Drug Profile1151
    Product Description1151
    Mechanism of Action1151
    R&D Progress1151
  cysteamine DR - Drug Profile1161
    Product Description1161
    Mechanism of Action1161
    R&D Progress1164
  deutetrabenazine ER - Drug Profile1201
    Product Description1201
    Mechanism of Action1201
    R&D Progress1202
  ED-11 - Drug Profile1221
    Product Description1221
    Mechanism of Action1221
    R&D Progress1221
  ENC-1001 - Drug Profile1231
    Product Description1231
    Mechanism of Action1231
    R&D Progress1231
  fisetin - Drug Profile1241
    Product Description1241
    Mechanism of Action1241
    R&D Progress1241
  Gene Therapy for Huntington Disease - Drug Profile1251
    Product Description1251
    Mechanism of Action1251
    R&D Progress1251
  Gene Therapy to Inhibit Huntingtin Protein for Huntington Disease - Drug Profile1261
    Product Description1261
    Mechanism of Action1261
    R&D Progress1261
  GM-609 - Drug Profile1271
    Product Description1271
    Mechanism of Action1271
    R&D Progress1271
  INT-41 - Drug Profile1281
    Product Description1281
    Mechanism of Action1281
    R&D Progress1282
  IONIS-HTTRx - Drug Profile1301
    Product Description1301
    Mechanism of Action1301
    R&D Progress1301
  JM-6 - Drug Profile1311
    Product Description1311
    Mechanism of Action1311
    R&D Progress1311
  JR-100 - Drug Profile1321
    Product Description1321
    Mechanism of Action1321
    R&D Progress1321
  JRP-655 - Drug Profile1331
    Product Description1331
    Mechanism of Action1331
    R&D Progress1331
  JRP-900 - Drug Profile1341
    Product Description1341
    Mechanism of Action1341
    R&D Progress1341
  KL-00148 - Drug Profile1351
    Product Description1351
    Mechanism of Action1351
    R&D Progress1351
  laquinimod sodium - Drug Profile1361
    Product Description1361
    Mechanism of Action1361
    R&D Progress1364
  lithium citrate - Drug Profile1401
    Product Description1401
    Mechanism of Action1401
    R&D Progress1401
  LM-22A4 - Drug Profile1411
    Product Description1411
    Mechanism of Action1411
    R&D Progress1412
  LM11A-31BHS - Drug Profile1431
    Product Description1431
    Mechanism of Action1431
    R&D Progress1432
  MP-101 - Drug Profile1451
    Product Description1451
    Mechanism of Action1451
    R&D Progress1451
  NI-302 - Drug Profile1461
    Product Description1461
    Mechanism of Action1461
    R&D Progress1461
  NNI-362 - Drug Profile1471
    Product Description1471
    Mechanism of Action1471
    R&D Progress1472
  NNI-370 - Drug Profile1491
    Product Description1491
    Mechanism of Action1491
    R&D Progress1491
  noscapine - Drug Profile1501
    Product Description1501
    Mechanism of Action1501
    R&D Progress1501
  NP-42T - Drug Profile1511
    Product Description1511
    Mechanism of Action1511
    R&D Progress1511
  NsG-33 - Drug Profile1521
    Product Description1521
    Mechanism of Action1521
    R&D Progress1521
  NSI-566 - Drug Profile1531
    Product Description1531
    Mechanism of Action1531
    R&D Progress1532
  NT-219 - Drug Profile1551
    Product Description1551
    Mechanism of Action1551
    R&D Progress1551
  NTCELL - Drug Profile1561
    Product Description1561
    Mechanism of Action1561
    R&D Progress1562
  NWL-154 - Drug Profile1581

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Huntington Disease - Pipeline Review, H1 2016" May 31, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Huntington-Disease-Pipeline-Review-H1-2016-2088-15907>
  
APA:
Global Markets Direct - Market Research. (2016). Huntington Disease - Pipeline Review, H1 2016 May 31, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Huntington-Disease-Pipeline-Review-H1-2016-2088-15907>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.